A Type B meeting between the FDA and Plus Therapeutics offered clarity and direction for the next steps in development of ...

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing ...

The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...

Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.